Your session is about to expire
← Back to Search
Brilaroxazine for Schizophrenia (RECOVER Trial)
RECOVER Trial Summary
This trial is to see if the drug Brilaroxazine is effective and safe for patients with acute schizophrenia compared to a placebo, over the short and long term.
RECOVER Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowRECOVER Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.RECOVER Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have been diagnosed with schizophrenia.I have a psychotic disorder not including schizophrenia, or behavior issues from substance abuse.I have had ECT for schizophrenia in the last 5 years.I have never received treatment for schizophrenia.I have a brain condition affecting my thinking or memory that may impact my study participation.My condition did not improve after two long treatments with the strongest doses of antipsychotic medication.I have used clozapine at some point in my life.My main diagnosis isn't schizophrenia, but another condition causing my symptoms.I haven't taken long-lasting antipsychotic medication recently.I haven't taken specific strong medications or stimulants in the last 28 days.I have a mental health condition, but it's not schizophrenia.I am between 18 and 65 years old.I have been diagnosed with schizophrenia.I am between 18 and 65 years old.I have been taking antipsychotic medication for at least 3 days before the study starts and will continue throughout.
- Group 1: RP5063 15 mg once daily
- Group 2: RP5063 (brilaroxazine) 50 mg once daily
- Group 3: Placebo
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are we looking for more participants in this experiment?
"The study is still recruiting patients, as evidenced by the listing on clinicaltrials.gov. The trial was first posted on January 24th, 2022 and has been edited most recently on April 1st, 2022."
Is the age limit for participants in this research project set at 50 years or younger?
"The age requirement to participate in this trial is between 18-65 years old. There are 47 other trials available for patients under the age of eighteen and 174 options for those over sixty-five."
Are there any harmful interactions associated with taking RP5063 (brilaroxazine) 50 mg daily?
"RP5063 (brilaroxazine) 50 mg once daily has received a score of 3 for safety. This is due to the fact that it is a Phase 3 trial, which provides some data supporting efficacy as well as multiple rounds of data supporting safety."
In how many places is this trial currently taking place?
"To make things more convenient for potential participants, this trial is being run out of 17 different sites. These locations include Bentonville, Garden Grove and Little Rock as well as 14 other cities."
How many people can join this trial at most?
"Yes, the clinical trial is still looking for patients. The study was originally posted on January 24th, 2022 and updated most recently on April 1st of the same year. They are recruiting 402 individuals from 17 hospitals or clinics."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger